[et_pb_section bb_built=”1″][et_pb_row][et_pb_column type=”4_4″][et_pb_text _builder_version=”3.13.1″]

A group of scientists from the Institute of Biotechnology and Biomedicine (IBB) of the Autonomous University of Barcelona (UAB) have identified a molecule that stops and reverses the neurodegeneration caused by Parkinson’s.

Parkinson’s disease is characterized by the accumulation of protein deposits in the neurons that produce dopamine in the form of amyloid fibers, which are aggregates formed mainly by the alpha-synuclein protein.

Now, the researchers, after analyzing thousands of molecules, have found one, called SynuClean-D, that inhibits the aggregation of the alpha-synuclein protein and breaks the already formed amyloid fibers, preventing the process that triggers the neurodegenerative disease from Parkinson.

Everything shows that a future the molecule they have identified, SynuClean-D, may have therapeutic applications to treat neurodegenerative diseases such as Parkinson’s confirmed the researcher of the UAB Salvador Ventura, coordinator of the research.

Once the molecule was identified, we proceeded with the biophysical characterization ‘in vitro’ of its inhibitory activity and a test of its action with cultures of human neuronal cells, before testing its behavior in the worm.

Once applied the experiment with the worm «Caenorhabdiiselegans», one of the animal models most used for the study of neurodegenerative diseases, the researchers could verify that, once administered through food, the molecule is able to reduce significantly the aggregation alpha-synuclein, preventing the spread of toxic aggregates, and, therefore, prevents the degeneration of dopaminergic neurons.

These and other innovations are now possible in Pharmamedic.

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]